{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:32:13Z","timestamp":1793147533986,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Treatment options for patients with recurrent superficial bladder cancer are limited, necessitating aggressive exploration of new treatment strategies that effectively prevent recurrence and progression to invasive disease. We assessed the effects of belinostat (previously PXD101), a novel histone deacetylase inhibitor, on a panel of human bladder cancer cell lines representing superficial and invasive disease, and on a transgenic mouse model of superficial bladder cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Growth inhibition and cell cycle distribution effect of belinostat on 5637, T24, J82, and RT4 urothelial lines were assessed. Ha-<jats:italic>ras<\/jats:italic> transgenic mice with established superficial bladder cancer were randomized to receive either belinostat or vehicle alone, and assessed for bladder weight, hematuria, gene expression profiling, and immunohistochemistry (IHC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Belinostat had a significant linear dose-dependent growth inhibition on all cell lines (IC<jats:sub>50<\/jats:sub> range of 1.0\u201310.0 \u03bcM). The 5637 cell line, which was derived from a superficial papillary tumor, was the most sensitive to treatment. Belinostat (100 mg\/kg, intraperitoneal, 5 days each week for 3 weeks) treated mice had less bladder weight (p &lt; 0.05), and no hematuria compared with 6\/10 control mice that developed at least one episode. IHC of bladder tumors showed less cell proliferation and a higher expression of p21<jats:sup>WAF1<\/jats:sup> in the belinostat-treated mice. Gene expression profile analysis revealed 56 genes significantly different in the treated group; these included the upregulation of p21<jats:sup>WAF1<\/jats:sup>, induction of core histone deacetylase (HDAC), and cell communication genes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our data demonstrate that belinostat inhibits bladder cancer and supports the clinical evaluation of belinostat for the treatment of patients with superficial bladder cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-5-49","type":"journal-article","created":{"date-parts":[[2007,10,12]],"date-time":"2007-10-12T18:13:27Z","timestamp":1192212807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo"],"prefix":"10.1186","volume":"5","author":[{"given":"Michael T","family":"Buckley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Chiriboga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Liebes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulshan","family":"Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean F","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Tien","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,12]]},"reference":[{"key":"209_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54: 8-29.","journal-title":"CA Cancer J Clin"},{"key":"209_CR2","unstructured":"Society AC. What are the key statistics for bladder cancer?. Accessed January 2007, [http:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html]"},{"key":"209_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/0008-5472.CAN-05-3017","volume":"66","author":"JK Earel","year":"2006","unstructured":"Earel JK, VanOosten RL, Griffith TS: Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006, 66: 499-507. 10.1158\/0008-5472.CAN-05-3017.","journal-title":"Cancer Res"},{"key":"209_CR4","first-page":"3578","volume":"9","author":"WK Kelly","year":"2003","unstructured":"Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003, 9: 3578-88.","journal-title":"Clin Cancer Res"},{"key":"209_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00280-006-0374-7","volume":"60","author":"A Tumber","year":"2007","unstructured":"Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M, Ritchie JW: The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol. 2007, 60: 275-83. 10.1007\/s00280-006-0374-7.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"209_CR6","first-page":"721","volume":"2","author":"JA Plumb","year":"2003","unstructured":"Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003, 2 (8): 721-728.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"209_CR7","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1074\/mcp.M600007-MCP200","volume":"5","author":"HC Beck","year":"2006","unstructured":"Beck HC, Nielsen EC, Matthiesen R, Jensen LH, Sehested M, Finn P, Grauslund M, Hansen AM, Jensen ON: Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics. 2006, 5 (7): 1314-1325. 10.1074\/mcp.M600007-MCP200.","journal-title":"Mol Cell Proteomics"},{"key":"209_CR8","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-06-0111","volume":"5","author":"X Qian","year":"2006","unstructured":"Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M: Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006, 5: 2086-2095. 10.1158\/1535-7163.MCT-06-0111.","journal-title":"Mol Cancer Ther"},{"key":"209_CR9","first-page":"3047","volume":"7","author":"MA Carducci","year":"2001","unstructured":"Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC: Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120 hr infusion schedule. Clin Cancer Res. 2001, 7: 3047-55.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"209_CR10","first-page":"718","volume":"8","author":"V Sandor","year":"2002","unstructured":"Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002, 8 (3): 718-728.","journal-title":"Clin Cancer Res"},{"key":"209_CR11","first-page":"3137","volume":"16S","author":"M Hansen","year":"2005","unstructured":"Hansen M, Gimsing P, Rasmussen A, Jensen PB, Knudsen LM: A Phase I Study of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Patients with Advanced Hematological Tumors (abstract). J Clin Oncology. ASCO Annual Meeting Proceedings. 2005, 16S: 3137-","journal-title":"J Clin Oncology. ASCO Annual Meeting Proceedings"},{"key":"209_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1: 194-202. 10.1038\/35106079.","journal-title":"Nat Rev Cancer"},{"key":"209_CR13","doi-asserted-by":"publisher","first-page":"29752","DOI":"10.1074\/jbc.270.50.29752","volume":"270","author":"XR Wu","year":"1995","unstructured":"Wu XR, Medina JJ, Sun TT: Selective interactions of UPIa and UPIb, two members of the transmembrane 4 superfamily, with distinct single transmembrane-domained proteins in differentiated urothelial cells. J Biol Chem. 1995, 270: 29752-9. 10.1074\/jbc.270.50.29752.","journal-title":"J Biol Chem"},{"key":"209_CR14","first-page":"3512","volume":"59","author":"ZT Zhang","year":"1999","unstructured":"Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR: Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999, 59: 3512-7.","journal-title":"Cancer Res"},{"key":"209_CR15","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1038\/sj.onc.1204315","volume":"20","author":"ZT Zhang","year":"2001","unstructured":"Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, Wu XR: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001, 20: 1973-80. 10.1038\/sj.onc.1204315.","journal-title":"Oncogene"},{"issue":"11","key":"209_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/0046-8177(92)90285-B","volume":"23","author":"B Czerniak","year":"1992","unstructured":"Czerniak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F, Koss LG: Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992, 23 (11): 1199-1204. 10.1016\/0046-8177(92)90285-B.","journal-title":"Hum Pathol"},{"issue":"2","key":"209_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/87.2.129","volume":"87","author":"JM Fitzgerald","year":"1995","unstructured":"Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA, Summerhayes IC: Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst. 1995, 87 (2): 129-133. 10.1093\/jnci\/87.2.129.","journal-title":"J Natl Cancer Inst"},{"key":"209_CR18","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0022-5347(05)67247-3","volume":"164","author":"E Shapiro","year":"2000","unstructured":"Shapiro E, Huang HY, Wu XR: Uroplakin and androgen receptor expression in the human fetal genital tract: insights into the development of the vagina. J Urol. 2000, 164: 1048-51. 10.1016\/S0022-5347(05)67247-3.","journal-title":"J Urol"},{"key":"209_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1172\/JCI30062","volume":"117","author":"L Mo","year":"2007","unstructured":"Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C, Sun TT, Wu XR: Hyperactivation of Ha-ras oncogene, but not Ink4a\/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest. 2007, 117: 314-325. 10.1172\/JCI30062.","journal-title":"J Clin Invest"},{"key":"209_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrc1697","volume":"5","author":"XR Wu","year":"2005","unstructured":"Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005, 5: 713-25. 10.1038\/nrc1697.","journal-title":"Nat Rev Cancer"},{"key":"209_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.toxlet.2006.10.012","volume":"168","author":"S Nair","year":"2007","unstructured":"Nair S, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, Jain MR, Liew C, Chan JY, Kong AN: Toxicogenomics of endoplasmic reticulum stress inducer tunicamycin in the small intestine and liver of Nrf2 knockout and C57BL\/6J mice. Toxicol Lett. 2007, 168: 21-39. 10.1016\/j.toxlet.2006.10.012.","journal-title":"Toxicol Lett"},{"key":"209_CR22","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.lfs.2006.06.019","volume":"79","author":"R Hu","year":"2006","unstructured":"Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, Lin W, Reddy B, Chan JY, Kong AN: Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci. 2006, 79: 1944-55. 10.1016\/j.lfs.2006.06.019.","journal-title":"Life Sci"},{"key":"209_CR23","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/jnci\/91.21.1869","volume":"91","author":"DB Agus","year":"1999","unstructured":"Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI: Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999, 91: 1869-76. 10.1093\/jnci\/91.21.1869.","journal-title":"J Natl Cancer Inst"},{"key":"209_CR24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0002-9440(10)62310-3","volume":"166","author":"JM Roth","year":"2005","unstructured":"Roth JM, Akalu A, Zelmanovich A, Policarpio D, Ng B, MacDonald S, Formenti S, Liebes L, Brooks PC: Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol. 2005, 166: 901-11.","journal-title":"Am J Pathol"},{"key":"209_CR25","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1200\/JCO.2005.01.136","volume":"23","author":"AL Hamilton","year":"2005","unstructured":"Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM: Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol. 2005, 23: 6107-16. 10.1200\/JCO.2005.01.136.","journal-title":"J Clin Oncol"},{"key":"209_CR26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0090-4295(00)00523-9","volume":"55","author":"NA Mungan","year":"2000","unstructured":"Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, Kiemeney LA: Gender differences in stage-adjusted bladder cancer survival. Urology. 2000, 55: 876-80. 10.1016\/S0090-4295(00)00523-9.","journal-title":"Urology"},{"key":"209_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0094-0143(05)70055-0","volume":"25","author":"GD Grossfeld","year":"1998","unstructured":"Grossfeld GD, Carroll PR: Evaluation of asymptomatic microscopic haematuria. Urol Clin North Am. 1998, 25: 661-76. 10.1016\/S0094-0143(05)70055-0.","journal-title":"Urol Clin North Am"},{"key":"209_CR28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ymthe.2006.07.009","volume":"14","author":"N H\u00f6ti","year":"2006","unstructured":"H\u00f6ti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R: Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther. 2006, 14: 768-78. 10.1016\/j.ymthe.2006.07.009.","journal-title":"Mol Ther"},{"key":"209_CR29","first-page":"5749","volume":"9","author":"MC Kutko","year":"2003","unstructured":"Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP: Histone Deacetylase Inhibitors Induce Growth Suppression and Cell Death in Human Rhabdomyosarcoma in vitro. Clin Cancer Res. 2003, 9: 5749-55.","journal-title":"Clin Cancer Res"},{"key":"209_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1124\/jpet.106.106658","volume":"319","author":"CL Chen","year":"2006","unstructured":"Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R: Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther. 2006, 319: 533-42. 10.1124\/jpet.106.106658.","journal-title":"J Pharmacol Exp Ther"},{"key":"209_CR31","doi-asserted-by":"publisher","first-page":"10014","DOI":"10.1073\/pnas.180316197","volume":"97","author":"VM Richon","year":"2000","unstructured":"Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci. 2000, 97: 10014-9. 10.1073\/pnas.180316197.","journal-title":"Proc Natl Acad Sci"},{"key":"209_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF02479423","volume":"18","author":"H Sawa","year":"2001","unstructured":"Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, Tamura Y, Satone A, Ide W, Hashimoto I, Kamada H: Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 2001, 18: 109-14. 10.1007\/BF02479423.","journal-title":"Brain Tumor Pathol"},{"key":"209_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1442-2042.2006.01344.x","volume":"13","author":"GC Li","year":"2006","unstructured":"Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ: Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol. 2006, 13: 581-6. 10.1111\/j.1442-2042.2006.01344.x.","journal-title":"Int J Urol"},{"key":"209_CR34","first-page":"6973","volume":"62","author":"M Sanchez-Carbayo","year":"2002","unstructured":"Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C: Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002, 62: 6973-80.","journal-title":"Cancer Res"},{"key":"209_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1749-6632.1999.tb09415.x","volume":"886","author":"Y Sowa","year":"1999","unstructured":"Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T: Histone deacetylase inhibitor activates the p21\/WAF1\/Cip1 gene promoter through the Sp1 sites. Ann N Y Acad Sci. 1999, 886: 195-9. 10.1111\/j.1749-6632.1999.tb09415.x.","journal-title":"Ann N Y Acad Sci"},{"key":"209_CR36","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.0307708100","volume":"101","author":"CY Gui","year":"2004","unstructured":"Gui CY, Ngo L, Xu WS, Richon VM, Marks PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA. 2004, 101: 1241-6. 10.1073\/pnas.0307708100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"209_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.onc.1207020","volume":"23","author":"V Chopin","year":"2004","unstructured":"Chopin V, Toillon RA, Jouy N, Le Bourhis X: P21(WAF1\/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 2004, 23: 21-9. 10.1038\/sj.onc.1207020.","journal-title":"Oncogene"},{"key":"209_CR38","first-page":"151","volume":"2","author":"KB Glaser","year":"2003","unstructured":"Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2003, 2: 151-63.","journal-title":"Mol Cancer Ther"},{"key":"209_CR39","doi-asserted-by":"publisher","first-page":"8302","DOI":"10.1128\/MCB.22.23.8302-8319.2002","volume":"22","author":"K Ghoshal","year":"2002","unstructured":"Ghoshal K, Datta J, Majumder S, Bai S, Dong X, Parthun M, Jacob ST: Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol. 2002, 22: 8302-19. 10.1128\/MCB.22.23.8302-8319.2002.","journal-title":"Mol Cell Biol"},{"key":"209_CR40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1081\/CNV-200055970","volume":"23","author":"F Pellegrini","year":"2005","unstructured":"Pellegrini F, Budman DR: Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 2005, 23: 264-73. 10.1081\/CNV-200055970.","journal-title":"Cancer Invest"},{"key":"209_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000079503","volume":"66","author":"T Chiba","year":"2004","unstructured":"Chiba T, Yokosuka O, Fukai K, Kojima H, Tada M, Arai M, Imazeki F, Saisho H: Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology. 2004, 66: 481-491. 10.1159\/000079503.","journal-title":"Oncology"},{"key":"209_CR42","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.3748\/wjg.v12.i44.7113","volume":"12","author":"J Qi","year":"2006","unstructured":"Qi J, Zhu YQ, Luo J, Tao WH: Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 2006, 12: 7113-7.","journal-title":"World J Gastroenterol"},{"key":"209_CR43","doi-asserted-by":"publisher","first-page":"13636","DOI":"10.1073\/pnas.94.25.13636","volume":"94","author":"HS Melkonyan","year":"1997","unstructured":"Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC, Tomei LD, Umansky SR: SARPS: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci USA. 1997, 94: 13636-41. 10.1073\/pnas.94.25.13636.","journal-title":"Proc Natl Acad Sci USA"},{"key":"209_CR44","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1210\/en.2005-1030","volume":"147","author":"L Qiao","year":"2006","unstructured":"Qiao L, Schaack J, Shao J: Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology. 2006, 147: 865-74. 10.1210\/en.2005-1030.","journal-title":"Endocrinology"},{"key":"209_CR45","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.urology.2005.12.011","volume":"67","author":"AM Johnson","year":"2006","unstructured":"Johnson AM, Conover DL, Huang J, Messing EM, Ning R, O'Connell MJ, Rossi MA, Sun TT, Wood RW, Wu XR, Reeder JE: Early detection and measurement of urothelial tumors in mice. Urology. 2006, 67: 1309-14. 10.1016\/j.urology.2005.12.011.","journal-title":"Urology"},{"key":"209_CR46","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","volume":"109","author":"I Gojo","year":"2007","unstructured":"Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE: Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007, 109: 2781-90.","journal-title":"Blood"},{"key":"209_CR47","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","volume":"13","author":"SS Ramalingam","year":"2007","unstructured":"Ramalingam SS, Parise RA, Ramananthan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP: Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies. Clin Cancer Res. 2007, 13: 3605-10. 10.1158\/1078-0432.CCR-07-0162.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-5-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:44:29Z","timestamp":1630453469000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-5-49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["209"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-5-49","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,12]]},"assertion":[{"value":"14 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"49"}}